Actelion – Listed on the SIX Swiss Exchange (ATLN) and is currently valued at 6 billion Swiss Francs, representing the largest capitalisation in Europe for a biotech company. Actelion’s first drug Tracleer®, is an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream.
Mentions in press and media 1